Viking Global Investors’s BridgeBio Pharma BBIO Stock Holding History

Viking Global Investors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$879M	Sell	11,842,434 -2,551,500	-18%	-$185M	2.46%	11
2025 Q4	$1.1B	Sell	14,393,934 -1,583,915	-10%	-$104M	2.92%	9
2025 Q3	$830M	Sell	15,977,849 -2,577,526	-14%	-$126M	2.16%	13
2025 Q2	$801M	Sell	18,555,375 -3,500,000	-16%	-$127M	2.32%	10
2025 Q1	$762M	Sell	22,055,375 -3,065,616	-12%	-$103M	2.42%	12
2024 Q4	$689M	Hold	25,120,991	–	–	2.23%	17
2024 Q3	$640M	Hold	25,120,991	–	–	2.33%	16
2024 Q2	$636M	Hold	25,120,991	–	–	2.45%	14
2024 Q1	$777M	Hold	25,120,991	–	–	2.89%	9
2023 Q4	$1.01B	Hold	25,120,991	–	–	3.71%	7
2023 Q3	$662M	Sell	25,120,991 -1,500,000	-6%	-$42.6M	2.69%	12
2023 Q2	$458M	Hold	26,620,991	–	–	1.87%	17
2023 Q1	$441M	Hold	26,620,991	–	–	2.07%	18
2022 Q4	$203M	Hold	26,620,991	–	–	1.02%	31
2022 Q3	$265M	Hold	26,620,991	–	–	1.22%	31
2022 Q2	$242M	Hold	26,620,991	–	–	1.11%	33
2022 Q1	$270M	Hold	26,620,991	–	–	1.09%	31
2021 Q4	$444M	Hold	26,620,991	–	–	1.28%	24
2021 Q3	$1.25B	Hold	26,620,991	–	–	3.42%	4
2021 Q2	$1.62B	Hold	26,620,991	–	–	4.92%	2
2021 Q1	$1.64B	Hold	26,620,991	–	–	4.88%	2
2020 Q4	$1.89B	Hold	26,620,991	–	–	5.21%	2
2020 Q3	$999M	Hold	26,620,991	–	–	3.61%	6
2020 Q2	$868M	Hold	26,620,991	–	–	3.75%	7
2020 Q1	$772M	Hold	26,620,991	–	–	4.02%	7
2019 Q4	$933M	Hold	26,620,991	–	–	4.37%	6
2019 Q3	$572M	Hold	26,620,991	–	–	2.98%	13
2019 Q2	$718M	Buy	+26,620,991	New	+$726M	3.22%	12

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors's BBIO Position: Q1 2026 in Review

Viking Global Investors reduced its BridgeBio Pharma (BBIO) stake by 18% in Q1 2026, selling an estimated $185M and leaving 11,842,434 shares worth $879M. The position accounts for 2.46% of the portfolio, ranked #11.

Viking Global Investors first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. The position peaked at $1.89B in Q4 2020. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Viking Global Investors held 11,842,434 shares of BridgeBio Pharma worth $879M as of Q1 2026.
Viking Global Investors sold 2,551,500 BridgeBio Pharma shares in Q1 2026, an estimated $185M.
BridgeBio Pharma made up 2.46% of Viking Global Investors's portfolio in Q1 2026, its #11 holding.
Viking Global Investors first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
Viking Global Investors's BridgeBio Pharma position peaked at $1.89B in Q4 2020.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Viking Global Investors's 13F filing for Q1 2026, filed 15 May 2026.